The safety and efficacy of full-versus reduced-dose betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Prevention With Extended-Duration Betrixaban (APEX) trial
AMERICAN HEART JOURNAL, cilt.185, ss.93-100, 2017 (SCI-Expanded)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 185
- Basım Tarihi: 2017
- Doi Numarası: 10.1016/j.ahj.2016.12.004
- Dergi Adı: AMERICAN HEART JOURNAL
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Sayfa Sayıları: ss.93-100
- Marmara Üniversitesi Adresli: Evet
Özet
Background The APEX trial assessed the safety and efficacy of extended-duration thromboprophylaxis using betrixaban versus standard dosing of enoxaparin among hospitalized, acutely ill medical patients. The 80-mg betrixaban dose was halved to 40 mg among subjects with severe renal insufficiency and those receiving a concomitant strong P-glycoprotein inhibitor.